SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-002040
Filing Date
2020-01-07
Accepted
2020-01-07 17:18:38
Documents
8
Period of Report
2020-01-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm201430-1_8k.htm 8-K 22744
2 EXHIBIT 4.1 tm201430-1_ex41.htm EX-4.1 108620
3 EXHIBIT 5.1 tm201430-1_ex51.htm EX-5.1 10887
4 EXHIBIT 10.1 tm201430-1_ex101.htm EX-10.1 244199
5 EXHIBIT 10.2 tm201430-1_ex102.htm EX-10.2 78873
6 EXHIBIT 99.1 tm201430-1_ex991.htm EX-99.1 8679
7 GRAPHIC image_001.jpg GRAPHIC 3413
8 GRAPHIC image_002.jpg GRAPHIC 3584
  Complete submission text file 0001104659-20-002040.txt   485167
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 20513951
SIC: 2836 Biological Products, (No Diagnostic Substances)